Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Operating Leases (2019 - 2025)

Keros Therapeutics filings provide 7 years of Operating Leases readings, the most recent being $16.9 million for Q4 2025.

  • On a quarterly basis, Operating Leases changed 0.0% to $16.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.9 million, a 0.0% change, with the full-year FY2025 number at $16.9 million, changed 0.0% from a year prior.
  • Operating Leases hit $16.9 million in Q4 2025 for Keros Therapeutics, up from $15.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $17.4 million in Q3 2024 to a low of $231000.0 in Q4 2021.
  • Median Operating Leases over the past 5 years was $13.4 million (2023), compared with a mean of $10.7 million.
  • Biggest five-year swings in Operating Leases: crashed 65.03% in 2021 and later skyrocketed 5484.42% in 2022.
  • Keros Therapeutics' Operating Leases stood at $231000.0 in 2021, then skyrocketed by 5484.42% to $12.9 million in 2022, then rose by 4.18% to $13.4 million in 2023, then grew by 25.63% to $16.9 million in 2024, then changed by 0.0% to $16.9 million in 2025.
  • The last three reported values for Operating Leases were $16.9 million (Q4 2025), $15.1 million (Q3 2025), and $15.7 million (Q2 2025) per Business Quant data.